GGrantIndex
← Leaderboards

Cynthia M Carlsson

University Of Wisconsin Madison

$8,045,616
Attributed
$8,045,616
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,045,616 · 9
VA$0 · 1

By mechanism

P30$5,420,228 · 2
R01$1,646,636 · 1
K23$884,833 · 2
M01$93,919 · 4
I01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Wisconsin Madison

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposCerebrospinal FluidMiddle AgeS DiseaseMagnetic Resonance ImagingCognitivePharmaceutical PreparationsAdultBrainWisconsinPre-ClinicalS Disease RiskNeuroimagingCohortAmyloidBiological MarkersBlood VesselsParticipantTau ProteinsPreventRecording Of Previous EventsImpaired CognitionFundingPlacebos

Grant awards (30)

Core B - Clinical Core$1,023,489
P30 · FY2025 · AG · contact PI
Core B - Clinical Core$1,030,472
P30 · FY2024 · AG · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2024 · VA · contact PI
Clinical Core$476,405
P30 · FY2023 · AG · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2023 · VA · contact PI
Clinical Core$628,462
P30 · FY2022 · AG · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2022 · VA · contact PI
Clinical Core$1,239,814
P30 · FY2021 · AG · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2021 · VA · contact PI
Clinical Core$547,224
P30 · FY2020 · AG · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2020 · VA · contact PI
Clinical Core$474,362
P30 · FY2019 · AG · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2019 · VA · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2018 · VA · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2017 · VA · contact PI
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults$0
I01 · FY2016 · VA · contact PI
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD$145,000
R01 · FY2013 · AG · contact PI
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD$489,569
R01 · FY2011 · AG · contact PI
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD$483,628
R01 · FY2010 · AG · contact PI
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD$528,439
R01 · FY2009 · AG · contact PI
Effect of Statins on Pathobiology of Alzheimer's Disease$194,377
K23 · FY2008 · AG · contact PI
Effect of Statins on Pathobiology of Alzheimer's Disease$190,862
K23 · FY2007 · AG · contact PI
EFFECT OF STATINS ON THE PATHOBIOLOGY OF ALZHEIMER'S DISEASE: THE ESPRIT TRIAL$4,366
M01 · FY2007 · RR · contact PI
IMPACT OF ATORVASTATIN ON CEREBRAL PERFUSION AND ENDOTHELIAL FUNCTION$1,021
M01 · FY2007 · RR · contact PI
Effect of Statins on Pathobiology of Alzheimer's Disease$186,043
K23 · FY2006 · AG · contact PI
EFFECT OF STATINS ON THE PATHOBIOLOGY OF ALZHEIMER'S DISEASE: THE ESPRIT TRIAL$36,305
M01 · FY2006 · RR · contact PI
Effect of Statins on Pathobiology of Alzheimer's Disease$184,718
K23 · FY2005 · AG
EFFECTS OF SIMVASTATIN ON THE PATHOBIOLOGY OF ALZHEIMER'S DISEASE: PAST STUDY$32,584
M01 · FY2005 · RR
Effect of Statins on Pathobiology of Alzheimer's Disease$128,833
K23 · FY2004 · AG
Effects of Simvastatin on the Pathobiology of Alzheimer's Disease: PAST Study$19,643
M01 · FY2004 · RR